Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D0D7KC
|
||||
| Former ID |
DAP001140
|
||||
| Drug Name |
Alvimopan
|
||||
| Synonyms |
Alvimopan anhydrous; LY 246736; LY246736; Adl 8-2698; Entereg (TN); Trans-3,4-dimethyl-4-(3-hydroxyphenyl) piperidine; Glycine, N-[2-[[4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]methyl]-1-oxo-3-phenylpropyl; 2-[[(2S)-2-benzyl-3-[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethylpiperidin-1-yl]propanoyl]amino]acetic acid
|
||||
| Drug Type |
Small molecular drug
|
||||
| Indication | Gastrointestinal disease; Pain [ICD9: 338, 356.0, 356.8, 780; ICD10:K00-K93, G64, G90.0, R52, G89] | Approved | [1], [2], [3] | ||
| Therapeutic Class |
Analgesics
|
||||
| Company |
GSK
|
||||
| Structure |
|
Download2D MOL |
|||
| Formula |
C25H32N2O4
|
||||
| InChI |
InChI=1S/C25H32N2O4/c1-18-16-27(12-11-25(18,2)21-9-6-10-22(28)14-21)17-20(24(31)26-15-23(29)30)13-19-7-4-3-5-8-19/h3-10,14,18,20,28H,11-13,15-17H2,1-2H3,(H,26,31)(H,29,30)/t18-,20-,25+/m0/s1
|
||||
| InChIKey |
UPNUIXSCZBYVBB-JVFUWBCBSA-N
|
||||
| CAS Number |
CAS 156053-89-3
|
||||
| PubChem Compound ID | |||||
| PubChem Substance ID |
11694298, 14782746, 14929630, 39473631, 57364430, 75544615, 93619728, 99443242, 103572184, 104179178, 113996613, 126574462, 126724760, 134224030, 135111682, 136008678, 137005188, 137445067, 152035895, 152258482, 160647317, 160967857, 162185566, 163125717, 163416638, 163884570, 164777755, 164826629, 175267928, 180371296, 184816790, 187051774, 204380366, 223554824, 226433297, 241036441, 249858481, 249865158, 250216916, 251916104, 251917452, 252075803, 252432676
|
||||
| SuperDrug ATC ID |
A06AH02
|
||||
| Target and Pathway | |||||
| Target(s) | Mu-type opioid receptor | Target Info | Antagonist | [4] | |
| KEGG Pathway | Neuroactive ligand-receptor interaction | ||||
| Estrogen signaling pathway | |||||
| Morphine addiction | |||||
| NetPath Pathway | TCR Signaling Pathway | ||||
| PANTHER Pathway | Heterotrimeric G-protein signaling pathway-Gi alpha and Gs alpha mediated pathway | ||||
| Heterotrimeric G-protein signaling pathway-Gq alpha and Go alpha mediated pathway | |||||
| Enkephalin release | |||||
| Pathway Interaction Database | IL4-mediated signaling events | ||||
| Reactome | Peptide ligand-binding receptors | ||||
| G alpha (i) signalling events | |||||
| WikiPathways | TCR Signaling Pathway | ||||
| GPCRs, Class A Rhodopsin-like | |||||
| Peptide GPCRs | |||||
| Opioid Signalling | |||||
| GPCR ligand binding | |||||
| GPCR downstream signaling | |||||
| References | |||||
| REF 1 | 2008 FDA drug approvals. Nat Rev Drug Discov. 2009 Feb;8(2):93-6. | ||||
| REF 2 | Emerging drugs for postoperative ileus. Expert Opin Emerg Drugs. 2007 Nov;12(4):619-26. | ||||
| REF 3 | (http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7471). | ||||
| REF 4 | Alvimopan for postoperative ileus. Am J Health Syst Pharm. 2009 Jul 15;66(14):1267-77. | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.